Greenspan N, Doherty P C
Hybridoma. 1982;1(2):149-59. doi: 10.1089/hyb.1.1982.1.149.
Mice injected with any influenza A virus develop a range of virus-immune cytotoxic T lymphocytes, some of which tend to be more lytic for cells expressing the virus used for priming (subtype-specific) while others are cross-reactive for targets infected with all influenza A viruses. Treatment with large doses of either of two monoclonal antibodies (which bind to the influenza virus hemagglutinin molecule) at 3-48 h after exposure to virus tends to selectively block the generation of the more subtype-specific cytotoxic T lymphocyte subset, although the magnitude of cross-reactive effector function may also be diminished. Inhibition that is less obviously selective is also seen for a third monoclonal antibody. A reasonable explanation for these findings is that there is afferent blockage at the level of T-cell recognition of the influenza virus hemagglutinin molecule expressed on stimulator cells. The inhibitory effect of the monoclonal antibody is apparently steric. Priming with parental strain virus followed by exposure to monoclonal antibody induces a population of cytotoxic T lymphocytes which manifest decreased cytotoxic activity for target cells infected with either the parental strain virus or with a variant virus to which the monoclonal antibody does not bind. A more practical consideration is that the administration of large doses of specific immunoglobulin may interfere with the development of cell-mediated immune mechanisms. This should be considered when developing possible therapeutic protocols using monoclonal antibodies.
注射任何甲型流感病毒的小鼠会产生一系列病毒免疫细胞毒性T淋巴细胞,其中一些对表达用于引发免疫的病毒的细胞(亚型特异性)具有更强的裂解作用,而另一些则对感染所有甲型流感病毒的靶标具有交叉反应性。在接触病毒后3至48小时用两种单克隆抗体(与流感病毒血凝素分子结合)中的任何一种大剂量治疗,往往会选择性地阻断更多亚型特异性细胞毒性T淋巴细胞亚群的产生,尽管交叉反应效应功能的程度也可能降低。对于第三种单克隆抗体,也观察到不太明显的选择性抑制作用。对这些发现的一个合理的解释是,在刺激细胞上表达的流感病毒血凝素分子的T细胞识别水平上存在传入阻断。单克隆抗体的抑制作用显然是空间位阻性的。用亲代毒株病毒进行免疫接种,然后接触单克隆抗体,会诱导出一群细胞毒性T淋巴细胞,这些细胞对感染亲代毒株病毒或单克隆抗体不结合的变异病毒的靶细胞表现出降低的细胞毒性活性。一个更实际的考虑是,大剂量特异性免疫球蛋白的给药可能会干扰细胞介导免疫机制的发展。在制定使用单克隆抗体的可能治疗方案时应考虑到这一点。